Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment

English version

Autoři: Jesse L. Yedinak ^aff001; William C. Goedel ^aff001; Kimberly Paull ^aff002; Rebecca Lebeau ^aff002; Maxwell S. Krieger ^aff001; Cheyenne Thompson ^aff002; Ashley L. Buchanan ^aff003; Tom Coderre ^aff004; Rebecca Boss ^aff005; Josiah D. Rich ^aff001; Brandon D. L. Marshall ^aff001
Působiště autorů: Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island, United States of America ^aff001; Executive Office of Health and Human Services, State of Rhode Island, Cranston, Rhode Island, United States of America ^aff002; Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, United States of America ^aff003; Office of the Governor, State of Rhode Island, Providence, Rhode Island, United States of America ^aff004; Department of Behavioral Healthcare, Developmental Disabilities and Hospitals, State of Rhode Island, Cranston, Rhode Island, United States of America ^aff005; Department of Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island, United States of America ^aff006
Vyšlo v časopise: Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment. PLoS Med 16(11): e32767. doi:10.1371/journal.pmed.1002963
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002963

Souhrn

Background

In light of the accelerating and rapidly evolving overdose crisis in the United States (US), new strategies are needed to address the epidemic and to efficiently engage and retain individuals in care for opioid use disorder (OUD). Moreover, there is an increasing need for novel approaches to using health data to identify gaps in the cascade of care for persons with OUD.

Methods and findings

Between June 2018 and May 2019, we engaged a diverse stakeholder group (including directors of statewide health and social service agencies) to develop a statewide, patient-centered cascade of care for OUD for Rhode Island, a small state in New England, a region highly impacted by the opioid crisis. Through an iterative process, we modified the cascade of care defined by Williams et al. for use in Rhode Island using key national survey data and statewide health claims datasets to create a cross-sectional summary of 5 stages in the cascade. Approximately 47,000 Rhode Islanders (5.2%) were estimated to be at risk for OUD (stage 0) in 2016. At the same time, 26,000 Rhode Islanders had a medical claim related to an OUD diagnosis, accounting for 55% of the population at risk (stage 1); 27% of the stage 0 population, 12,700 people, showed evidence of initiation of medication for OUD (MOUD, stage 2), and 18%, or 8,300 people, had evidence of retention on MOUD (stage 3). Imputation from a national survey estimated that 4,200 Rhode Islanders were in recovery from OUD as of 2016, representing 9% of the total population at risk. Limitations included use of self-report data to arrive at estimates of the number of individuals at risk for OUD and using a national estimate to identify the number of individuals in recovery due to a lack of available state data sources.

Conclusions

Our findings indicate that cross-sectional summaries of the cascade of care for OUD can be used as a health policy tool to identify gaps in care, inform data-driven policy decisions, set benchmarks for quality, and improve health outcomes for persons with OUD. There exists a significant opportunity to increase engagement prior to the initiation of OUD treatment (i.e., identification of OUD symptoms via routine screening or acute presentation) and improve retention and remission from OUD symptoms through improved community-supported processes of recovery. To do this more precisely, states should work to systematically collect data to populate their own cascade of care as a health policy tool to enhance system-level interventions and maximize engagement in care.

Klíčová slova:

Drug therapy – HIV infections – Health care policy – Opioids – Health services administration and management – United States – Heroin – Rhode Island

Zdroje

1. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–52. doi: 10.15585/mmwr.mm655051e1 28033313

2. Socías ME, Volkow N, Wood E. Adopting the “cascade of care” framework: an opportunity to close the implementation gap in addiction care? Addiction. 2016;111:2079–81. doi: 10.1111/add.13479 27412876

3. Simmons R, Ireland G, Irving W, Hickman M, Sabin C, Ijaz S, et al. Establishing the cascade of care for hepatitis C in England—benchmarking to monitor impact of direct acting antivirals. J Viral Hepat. 2018;25:482–90. doi: 10.1111/jvh.12844 29239130

4. Vagenas P, Azar MM, Copenhaver MM, Springer SA, Molina PE, Altice FL. The impact of alcohol use and related disorders on the HIV continuum of care: a systematic review: alcohol and the HIV Continuum of Care. Curr HIV/AIDS Rep. 2015;12:421–36. doi: 10.1007/s11904-015-0285-5 26412084

5. Cooper CL. Now is the time to quickly eliminate barriers along the hepatitis C cascade of care. J Infect Dis. 2018;217:1858–60. doi: 10.1093/infdis/jiy117 29534217

6. Shih Y-CT, Ganz PA, Aberle D, Abernethy A, Bekelman J, Brawley O, et al. Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol. 2013;31:4151–7. doi: 10.1200/JCO.2013.51.0651 24127450

7. Norrving B, Kissela B. The global burden of stroke and need for a continuum of care. Neurology. 2013;80:S5–12. doi: 10.1212/WNL.0b013e3182762397 23319486

8. Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy. 2017;47:107–16. doi: 10.1016/j.drugpo.2017.07.006 28797497

9. Gardner EM, Daniloff E, Thrun MW, Reirden DH, Davidson AJ, Johnson SC, et al. Initial linkage and subsequent retention in HIV care for a newly diagnosed HIV-infected cohort in Denver, Colorado. J Int Assoc Provid AIDS Care. 2013;12:384–90. doi: 10.1177/2325957413500532 23962912

10. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793–800. doi: 10.1093/cid/ciq243 21367734

11. Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, et al. The population level cascade of care for hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine. 2016;12:189–95. doi: 10.1016/j.ebiom.2016.08.035 27596150

12. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. BMJ Glob Health. 2016;1:e000010. doi: 10.1136/bmjgh-2015-000010 28588933

13. Hull MW, Wu Z, Montaner JS. Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Curr Opin HIV AIDS. 2012;7:579–86. doi: 10.1097/COH.0b013e3283590617 23076123

14. Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis. 2013;57:1164–71. doi: 10.1093/cid/cit420 23797289

15. Williams A, Nunes E, Olfson M. To battle the opioid overdose epidemic, deploy the “cascade of care” model. Health Affairs Blog. 2017 Mar 13 [cited 2019 Oct 16]. http://healthaffairs.org/blog/2017/03/13/to-battle-the-opioid-overdose-epidemic-deploy-the-cascade-of-care-model/.

16. Brinkley-Rubinstein L, Zaller N, Martino S, Cloud DH, McCauley E, Heise A, et al. Criminal justice continuum for opioid users at risk of overdose. Addict Behav. 2018;86:104–10. doi: 10.1016/j.addbeh.2018.02.024 29544869

17. Williams AR, Nunes EV, Bisaga A, Pincus HA, Johnson KA, Campbell AN, et al. Developing an opioid use disorder treatment cascade: A review of quality measures. J Subst Abuse Treat. 2018;91:57–68. doi: 10.1016/j.jsat.2018.06.001 29910015

18. Watkins KE, Paddock SM, Hudson TJ, Ounpraseuth S, Schrader AM, Hepner KA, et al. Association between process measures and mortality in individuals with opioid use disorders. Drug Alcohol Depend. 2017;177:307–14. doi: 10.1016/j.drugalcdep.2017.03.033 28662975

19. Crystal S, Akincigil A, Bilder S, Walkup JT. Studying prescription drug use and outcomes with medicaid claims data: strengths, limitations, and strategies. Med Care. 2007;45:S58–65. doi: 10.1097/MLR.0b013e31805371bf 17909385

20. Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M. Development of a cascade of care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45:1–10. doi: 10.1080/00952990.2018.1546862 30675818

21. Leshner AI, Dzau VJ. Medication-based treatment to address opioid use disorder. JAMA. 2019;321:2071–2. doi: 10.1001/jama.2019.5523 31046072

22. Raimondo GM. Rhode Island Overdose Prevention and Intervention Task Force action plan. Providence: Office of the Governor; 2016 [cited 2017 Oct 1]. http://www.governor.ri.gov/documents/press/051116.pdf.

23. Marshall B. Using data to guide and evaluate responses to the opioid crisis: Rhode Island’s drug overdose dashboard. National Network of Libraries of Medicine New England Region Repository; 2018 [cited 2019 Oct 16]. https://escholarship.umassmed.edu/ner/54.

24. Evashwick C. Creating the continuum of care. Health Matrix. 1989;7:30–9.

25. US Department of Health and Human Services, Office of the Surgeon General. Facing addiction in America: the Surgeon General’s report on alcohol, drugs, and health. Washington (DC): US Department of Health and Human Services; 2016.

26. Haber N, Pillay D, Porter K, Bärnighausen T. Constructing the cascade of HIV care: methods for measurement. Curr Opin HIV AIDS. 2016;11:102–8. doi: 10.1097/COH.0000000000000212 26545266

27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition (DSM-5). Washington (DC): American Psychiatric Association; 2013.

28. Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder: treatment improvement protocol—TIP 63. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2019 [cited 2019 Oct 16] https://store.samhsa.gov/system/files/tip63_fulldoc_052919_508.pdf.

29. Harris AHS, Weisner CM, Chalk M, Capoccia V, Chen C, Thomas CP. Specifying and pilot testing quality measures for the American Society of Addiction Medicine’s standards of care. J Addict Med. 2016;10:148–55. doi: 10.1097/ADM.0000000000000203 26933875

30. Peña C. Updating HEDIS—what you need to know. NCQA Blog. 2017 Jul 10 [cited 2018 Jun 11]. http://blog.ncqa.org/updating-hedis/.

31. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2012.

32. Substance Abuse and Mental Health Services Administration. Federal guidelines for opioid treatment programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2015 [cited 2019 Oct 16]. https://store.samhsa.gov/system/files/pep15-fedguideotp.pdf.

33. Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 2009;99:280–95. doi: 10.1016/j.drugalcdep.2008.08.003 18929451

34. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170:1155–60. doi: 10.1001/archinternmed.2010.140 20625025

35. Kerber KJ, de Graft-Johnson JE, Bhutta ZA, Okong P, Starrs A, Lawn JE. Continuum of care for maternal, newborn, and child health: from slogan to service delivery. Lancet. 2007;370:1358–69. doi: 10.1016/S0140-6736(07)61578-5 17933651

36. Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374:363–71. doi: 10.1056/NEJMra1511480 26816013

37. Kelly JF, Bergman B, Hoeppner BB, Vilsaint C, White WL. Prevalence and pathways of recovery from drug and alcohol problems in the United States population: implications for practice, research, and policy. Drug Alcohol Depend. 2017;181:162–9. doi: 10.1016/j.drugalcdep.2017.09.028 29055821

38. Hoffman LA, Vilsaint C, Kelly JF. Recovery from opioid problems in the US population: prevalence, pathways, and psychological well-being. J Addict Med. 2019 Aug 2. doi: 10.1097/ADM.0000000000000561 31385848

39. Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2019 [cited 2019 May 3]. https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health.

40. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2014:CD002207.

41. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;2009:CD002209.

42. National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Committee on Medication-Assisted Treatment for Opioid Use Disorder. Medications for opioid use disorder save lives. Washington (DC): National Academies Press; 2019. doi: 10.17226/25310 30896911

43. National Quality Forum. Continuity of pharmacotherapy for opioid use disorder. NQF #3175. National Quality Forum. 2017 Jun 28 [cited 2019 Oct 18]. http://www.qualityforum.org/QPS/3175.

44. Substance Abuse and Mental Health Services Administration. Substance Abuse and Mental Health Data Archive. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2019 [cited 2019 Aug]. https://rdas.samhsa.gov/#/.

45. Rhode Island Department of Health. HealthFacts RI database: Providence: Rhode Island Department of Health; 2019 [cited 2019 May 3]. http://www.health.ri.gov/data/healthfactsri/.

46. Rhode Island Department of Health. Prescription Drug Monitoring Program. Providence: Rhode Island Department of Health; 2019 [cited 2019 Jun 12]. http://www.health.ri.gov/healthcare/medicine/about/prescriptiondrugmonitoringprogram/.

47. Rhode Island Department of Behavioral Healthcare, Developmental Disabilities and Hospitals. Reporting requirements. Cranston: Rhode Island Department of Behavioral Healthcare, Developmental Disabilities and Hospitals; 2019 [cited 2019 Jun 12]. http://www.bhddh.ri.gov/sections/reporting.php.

48. Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2017. Data on substance abuse treatment facilities. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2018 [cited 2019 Oct 16]. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/2017_NSSATS.pdf.

49. Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35:22–35. doi: 10.1080/10550887.2016.1100960 26467975

50. Volkow ND. Medications for opioid use disorder: bridging the gap in care. Lancet. 2018;391:285–7. doi: 10.1016/S0140-6736(17)32893-3 29150199

51. Barocas JA, White LF, Wang J, Walley AY, LaRochelle MR, Bernson D, et al. Estimated prevalence of opioid use disorder in Massachusetts, 2011–2015: a capture-recapture analysis. Am J Public Health. 2018;108:1675–81. doi: 10.2105/AJPH.2018.304673 30359112

52. Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393:1760–72. doi: 10.1016/S0140-6736(18)33078-2 30878228

53. Samuels EA, McDonald JV, McCormick M, Koziol J, Friedman C, Alexander-Scott N. Emergency department and hospital care for opioid use disorder: implementation of statewide standards in Rhode Island, 2017–2018. Am J Public Health. 2019;109:263–6. doi: 10.2105/AJPH.2018.304847 30571304

54. Sharfstein JM, Olsen Y. JAMA forum: making amends for the opioid epidemic. news@JAMA. 2019 Mar 7 [cited 2019 May 3]. https://newsatjama.jama.com/2019/03/07/jama-forum-making-amends-for-the-opioid-epidemic/.

55. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169:137–45. doi: 10.7326/M17-3107 29913516

56. Ashford RD, Pennelle O, Canode B, Kosloff J, Desikan R, Galea S, et al. It’s time to measure addiction recovery rates, not just addiction rates. STAT. 2018 Aug 30 [cited 2019 May 1]. https://www.statnews.com/2018/08/30/measure-addiction-recovery-rates/.

57. Jack HE, Oller D, Kelly J, Magidson JF, Wakeman SE. Addressing substance use disorder in primary care: the role, integration, and impact of recovery coaches. Subst Abus. 2018;39:307–14. doi: 10.1080/08897077.2017.1389802 28991516

58. Waye KM, Goyer J, Dettor D, Mahoney L, Samuels EA, Yedinak JL, et al. Implementing peer recovery services for overdose prevention in Rhode Island: an examination of two outreach-based approaches. Addict Behav. 2019;89:85–91. doi: 10.1016/j.addbeh.2018.09.027 30278306

59. Kelly JF, Hoeppner B. A biaxial formulation of the recovery construct. Addict Res Theory. 2015;23:5–9.

60. Kelly JF, Greene MC, Bergman BG. Beyond abstinence: changes in indices of quality of life with time in recovery in a nationally representative sample of U.S. adults. Alcohol Clin Exp Res. 2018;42:770–80. doi: 10.1111/acer.13604 29473966

61. White WL, Kelly JF, Roth JD. New addiction-recovery support institutions: mobilizing support beyond professional addiction treatment and recovery mutual aid. J Groups Addict Recover. 2012;7:297–317.

62. Hennessy EA. Recovery capital: a systematic review of the literature. Addict Res Theory. 2017;25:349–60.

63. Laudet AB, White WL. Recovery capital as prospective predictor of sustained recovery, life satisfaction, and stress among former poly-substance users. Subst Use Misuse. 2008;43:27–54. doi: 10.1080/10826080701681473 18189204

64. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System: about BRFSS. Atlanta: Centers for Disease Control and Prevention; 2019 [cited 2019 May 2]. https://www.cdc.gov/brfss/about/index.htm.

65. Vilsaint CL, Kelly JF, Bergman BG, Groshkova T, Best D, White W. Development and validation of a Brief Assessment of Recovery Capital (BARC-10) for alcohol and drug use disorder. Drug Alcohol Depend. 2017;177:71–6. doi: 10.1016/j.drugalcdep.2017.03.022 28578224

66. Groshkova T, Best D, White W. The assessment of recovery capital: properties and psychometrics of a measure of addiction recovery strengths. Drug Alcohol Rev. 2013;32:187–94. doi: 10.1111/j.1465-3362.2012.00489.x 22882622

67. Kelly JF, Abry AW, Milligan CM, Bergman BG, Hoeppner BB. On being “in recovery”: a national study of prevalence and correlates of adopting or not adopting a recovery identity among individuals resolving drug and alcohol problems. Psychol Addict Behav. 2018;32:595–604. doi: 10.1037/adb0000386 30070538

68. PreventOverdose, RI. Medication-assisted treatment data. PreventOverdose, RI; 2019 [cited 2019 Aug 12]. https://preventoverdoseri.org/medication-assisted-therapy/.